SCHEDULE 13D/A

Monte Rosa Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 61225M102

Event date: 2026-03-17

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• New Enterprise Associates 17, L.P.Reported CIK 0001768564

  Shares: 7,692,298.00 · Class: 9.6%

• NEA Partners 17, L.P.Reported CIK 0001796820

  Shares: 7,692,298.00 · Class: 9.6%

• NEA 17 GP, LLCReported CIK 0001796821

  Shares: 7,692,298.00 · Class: 9.6%

• Forest BaskettReported CIK 0001277631

  Shares: 7,692,298.00 · Class: 9.6%

• Ali BehbahaniReported CIK 0001613867

  Shares: 7,797,030.00 · Class: 9.7%

• Carmen ChangReported CIK 0001746342

  Shares: 7,692,298.00 · Class: 9.6%

• Anthony A. Florence, Jr.Reported CIK 0001559827

  Shares: 7,692,298.00 · Class: 9.6%

• Mohamad H. MakhzoumiReported CIK 0001630226

  Shares: 7,692,298.00 · Class: 9.6%

• Edward T. MathersReported CIK 0001328625

  Shares: 7,692,298.00 · Class: 9.6%

• Scott D. SandellReported CIK 0001237289

  Shares: 7,692,298.00 · Class: 9.6%

• Paul WalkerReported CIK 0001553150

  Shares: 7,692,298.00 · Class: 9.6%

• Rick YangReported CIK 0001851328

  Shares: 7,692,298.00 · Class: 9.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.